Ras inhibitor RSC-1255
Term · Oncology and biomedicine · MLC-T-ONC-016369
An orally bioavailable pan-mutant and wild-type Ras inhibitor, with potential antineoplastic activity. Upon oral administration, Ras inhibitor RSC-1255 selectively targets, binds to and inhibits both wild-type and mutated forms of Ras, thereby inhibiting Ras-dependent signaling and inhibits proliferation of tumor cells in which Ras is overexpressed and/or mutated. Ras serves an important role in cell signaling, division and differentiation. Mutations of Ras may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.
| Identifier | MLC-T-ONC-016369 |
|---|---|
| Field | Oncology and biomedicine |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-016369",
"term": "Ras inhibitor RSC-1255",
"field": "Oncology and biomedicine",
"definition": "An orally bioavailable pan-mutant and wild-type Ras inhibitor, with potential antineoplastic activity. Upon oral administration, Ras inhibitor RSC-1255 selectively targets, binds to and inhibits both wild-type and mutated forms of Ras, thereby inhibiting Ras-dependent signaling and inhibits proliferation of tumor cells in which Ras is overexpressed and/or mutated. Ras serves an important role in cell signaling, division and differentiation. Mutations of Ras may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.",
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/ras-inhibitor-rsc-1255/"
}
Record 14,082 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.